Qyuns Therapeutics (HKG: 2509) announced that it has entered into an out‑license agreement with Caldera Therapeutics, Inc. covering a preclinical‑stage bispecific antibody program targeting TL1A and IL‑17 (specifically IL‑17A and IL‑17A/F), in a deal worth a USD 30 million upfront payment plus up to USD 750 million in milestone payments and tiered royalties — the companies’ second licensing collaboration following the April 2025 QX030N deal.
Transaction Snapshot
| Item | Detail |
|---|---|
| Licensor | Qyuns Therapeutics (HKG: 2509) |
| Licensee | Caldera Therapeutics, Inc. |
| Asset | Preclinical‑stage bispecific antibody program targeting TL1A and IL‑17 (IL‑17A and IL‑17A/F) |
| Rights Granted | Exclusive, royalty‑bearing, transferable, sublicensable right to research, develop, register, manufacture, and commercialize product candidates arising from the Licensed Program, worldwide |
| Upfront Payment | USD 30 million – one‑time, non‑refundable, non‑creditable |
| Milestone Payments | Up to USD 750 million, subject to clinical development, regulatory, and commercial milestones |
| Royalties | Tiered royalties on net sales during a specified period after first commercial sale |
| Announcement Date | 5 Nov 2026 |
Program Profile & Mechanism Rationale
- Bispecific Design: The program simultaneously targets TL1A (TNF‑like ligand 1A) and IL‑17 cytokines — specifically IL‑17A and IL‑17A/F — combining two validated inflammatory pathways into a single molecule.
- Stage: Preclinical, with Caldera assuming responsibility for research, development, registration, manufacturing, and commercialization worldwide under the license terms.
- Therapeutic Area: Both TL1A and IL‑17 are prominent targets in autoimmune and inflammatory diseases, including inflammatory bowel disease and related immune‑mediated conditions; a dual‑targeting bispecific represents a differentiated next‑generation approach.
- Comprehensive Rights Transfer: The exclusive, sublicensable, worldwide grant gives Caldera full commercial control of the program, while Qyuns retains economics through the upfront, milestone, and royalty structure.
Expanding Qyuns–Caldera Partnership
| Date | Transaction | Asset | Value |
|---|---|---|---|
| Apr 2025 | Licensing collaboration | QX030N – autoimmune bispecific antibody | Transaction value exceeding USD 550 million |
| Nov 2026 | Out‑license agreement | TL1A × IL‑17 (IL‑17A / IL‑17A/F) bispecific program | USD 30 million upfront + up to USD 750 million milestones + tiered royalties |
Market Impact & Outlook
- Repeat Partnership Signal: Caldera’s second licensing deal with Qyuns within roughly 19 months — following the USD 550+ million QX030N collaboration — reflects strong licensee confidence in Qyuns’s bispecific antibody discovery platform.
- Hot Target Convergence: TL1A has emerged as one of the most actively pursued targets in autoimmune drug development; pairing it with IL‑17A/F positions the program at the frontier of next‑generation immunology assets.
- Monetizing Preclinical Innovation: Securing a USD 30 million non‑refundable upfront for a preclinical program underscores the market value of differentiated bispecific designs even at early stages.
- Capital‑Efficient Model: Out‑licensing with milestone and royalty economics allows Qyuns to convert R&D output into near‑term cash flow while retaining long‑term upside, without bearing global development and commercialization costs.
- Watch Items: Caldera’s IND‑enabling progress and clinical advancement of the TL1A × IL‑17 program, milestone achievement trajectory, and potential further expansion of the Qyuns–Caldera alliance.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the out‑license agreement between Qyuns Therapeutics and Caldera Therapeutics, including the achievement of development, regulatory, and commercial milestones, potential royalty income, and the clinical progression of the licensed bispecific program. Actual results may differ due to risks including preclinical and clinical development outcomes, regulatory review, milestone attainment uncertainty, commercialization execution by the licensee, and competitive dynamics.-Fineline Info & Tech
